Actively Recruiting
Auriculo-Nerve Stimulation on Post-Operative Opioid Requirement
Led by Jacques E. Chelly · Updated on 2026-01-08
286
Participants Needed
4
Research Sites
205 weeks
Total Duration
On this page
Sponsors
J
Jacques E. Chelly
Lead Sponsor
M
Masimo Corporation
Collaborating Sponsor
AI-Summary
What this Trial Is About
The NSS-2 BRIDGE® device (NSS stands for Neuro-Stimulation System) is a disposable device that stimulates the branches of cranial nerves and of the superficial cervical plexus innervating the ear. Because the stimulation of the nerves of the ear by the NSS-2 BRIDGE® device (NBD®) has been shown to modulate pain pathways in rodents, decrease abdominal pain in adolescents with inflammatory bile syndrome and due to the results of our preliminary pilot study, the investigators hypothesized that this technique may also be effective in reducing the requirement for postoperative opioids and provide a non-pharmacological alternative to perioperative opioid use. To establish the role that the stimulation of the nerves of the ear may have in reducing postoperative opioid requirement, the investigators are proposing to conduct a randomized, placebo controlled study in patients undergoing open abdominal or pelvic surgery requiring at least 5 days of hospitalization. Subjects who have signed an informed consent will be randomized in 2 groups (active NBD® group or inactive NBD® group). Furthermore, since preoperative and postoperative mood disorders have been shown to increase postoperative pain levels and opioid requirement by up to 50%, the investigators further hypothesize that the stimulation of the ear nerves by the NSS-2 BRIDGE® effects may be in part mediated by a reduction of the level of anxiety, depression and catastrophizing as assessed using validated questionnaires.
CONDITIONS
Official Title
Auriculo-Nerve Stimulation on Post-Operative Opioid Requirement
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Over 18 years of age
- Scheduled for elective open primary abdominal and pelvic colorectal cancer resection surgery or living-donor liver transplant surgery following the ERAS protocol
- Expected hospital stay of approximately 5 days
You will not qualify if you...
- Unable to give consent as determined by medical or surgical team
- Clinical evidence of anxiety, depression, or suicidal ideation based on medical history and psychosocial testing
- Chronic pain conditions or daily opioid use of 60 mg oral morphine equivalent or more
- True allergy to all opioid medications
- History or current alcohol or drug abuse for at least 3 months
- Surgery performed laparoscopically
- Non-elective surgery
- Pregnancy
- Contraindications to NSS-2 BRIDGE use, including cardiac pacemaker, hemophilia, psoriasis, or ear eczema
- Post-surgery intubation with sedation or fentanyl infusion
- Rapid recovery surgeries
- Diagnosed seizure disorder
- Use of dexmedetomidine in ICU
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 4 locations
1
University of Pittsburgh Medical Center - Magee-Womens Hospital
Pittsburgh, Pennsylvania, United States, 15213
Actively Recruiting
2
UPMC Montefiore Hospital
Pittsburgh, Pennsylvania, United States, 15213
Actively Recruiting
3
University of Pittsburgh Medical Center - Shadyside Hospital
Pittsburgh, Pennsylvania, United States, 15232
Actively Recruiting
4
University of Pittsburgh Medical Center - Passavant Hospital
Pittsburgh, Pennsylvania, United States, 15237
Actively Recruiting
Research Team
A
Amy Monroe, MPH, MBA
CONTACT
C
Carly Riedmann, MPH
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
QUADRUPLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here